REGENXBIO Corp (RGNX) - Bozor kapitallashuvining balans qiymatiga nisbati
REGENXBIO Inc. (RGNX) narxlar grafigi global korporatsiyalar bilan hamkorlik va DNK laboratoriyalari bilan birlashishlar orqali gen terapiyalarini ishlab chiquvchi kompaniyaning dinamikasini aks ettiradi. 5.42 darajasidagi rentabellik viral vektor litsenziyalashdan tushadigan royalti to'lovlari hisobiga ta'minlanmoqda, garchi sug'urta to'lovlari kelajakdagi mahsulotlarning qiymatini cheklasa-da. Operatsion model ishlab chiqarish va sinovlarni autsorsing qilishga tayanadi, bu esa biznesni haddan tashqari katta kapital xarajatlardan xalos qiladi.
%20Kapitallashuvning%20balans%20qiymatiga%20nisbati&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_RGNX_-_REGENXBIO-Inc._-_Capitalization-to-Book-Value-Ratio "RGNX: regenxbio.com Bozor qiymatining balans qiymatiga nisbati 04.07.2022 - 29.10.2026 | 👁️GURU.Markets👁️")
REGENXBIO Inc (RGNX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati REGENXBIO Inc.|RGNX - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning kapitalga nisbati Regenxbio|RGNX - Kompaniyaning umumiy yig'indi qarzi|Balans kapitallashuviga qarzlar Regenxbio|RGNX - Uzoq muddatli qarzdorlik|Kompaniyaning qisqa muddatli qarzlari REGENXBIO
Kompaniyaning har tomonlama tahlili:REGENXBIO Inc. - RGNX
Intellektual kapital va NAV Technology patent platformasi raqobatchilar uchun fundamental kirish to'sig'ini yaratib, REGENXBIO Inc. (RGNX) kompaniyasining nomoddiy aktivlarining yuqori baholanishini ta'minlaydi. Bozor kapitalizatsiyasining buxgalteriya qiymatiga nisbatini tahlil qilish orqali investor sof aktivlardan yuqori bo'lgan bozor premiumini baholaydi: birga yaqinlashgan nisbat aktivlar qiymatining pasayish xavfini bildiradi, sezilarli farq esa gen terapiyasi istiqbollarining adolatli qayta baholanganini tasdiqlaydi.
REGENXBIO Inc. raqobatchilari
TEM (Tempus Labs) - Kapitallashuvning sof aktivlarga nisbati|Kapitallashuvning balans qiymatiga nisbati QGEN|IONS (Ionis) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati RGEN (Repligen Corp)|Bozor qiymatining balans qiymatiga nisbati Avidity (RNA)|CRISPR - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|Bozor kapitallashuvining balans qiymatiga nisbati ultragenyx.com RARE|BEAM - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati SRPT (Sarepta Therapeutics)|TWST: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti 10x (TXG)|NTLA (Intellia Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|STOK - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati BLFS|WVE - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Maze Tx MAZE|SION: Kapitallashuvning balans qiymatiga nisbati|PRME: Kapitallashuvning sof aktivlarga nisbati|TSHA (tayshagtx.com) - Kapitallashuvning balans qiymatiga nisbati|QURE: Bozor kapitallashuvining balans qiymatiga nisbati|MGTX (MeiraGTx Holdings) - Bozor qiymatining balans qiymatiga nisbati|SLDB (Solid Bio) - Bozor kapitallashuvining balans qiymatiga nisbati|Ocugen Pharma (OCGN) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Pacific Biosciences (PACB)|BNTC - Bozor qiymatining balans qiymatiga koeffitsiyenti|Design Therapeutics, Inc. - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati RCKT|4D Molecular Therapeutics Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Lexeo Therapeutics LXEO|korrobio.com (KRRO) - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati EDIT|SLN (Silence Therapeutics plc) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati ProQR Therapeutics NV (PRQR)|Kapitallashuvning sof aktivlarga nisbati CDXS (Codexis, Inc.)|Balans qiymatiga nisbatan bozor kapitallashuvi Sangamo BioSciences|Bozor qiymatining balans qiymatiga nisbati Nautilus Bio NAUT|Balans qiymatiga nisbatan bozor qiymati MGX|Precision BioSciences - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati Generation Bio Co. (GBIO)|Boundless Bio, Inc (BOLD) - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati XCUR|Kapitallashuvning sof aktivlarga nisbati IMNN|Kapitallashuvning balans qiymatiga nisbati PHIO (RXi Pharmaceuticals)|Bozor kapitallashuvining balans qiymatiga nisbati MBIO|transcodetherapeutics.com - Kapitallashuvning balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Bionano Genomics BNGO|APDN: Kapitallashuvning balans qiymatiga nisbati|bluebird bio, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|IPA - Bozor kapitallashuvining balans qiymatiga nisbati|Omega Therapeutics, Inc. (OMGA) - Bozor qiymatining balans qiymatiga nisbati|Singular Genomics Systems, Inc. - Balans qiymatiga nisbatan bozor qiymati|RGLS (Regulus Therapeutics Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Syros Pharmaceuticals, Inc SYRS|Bozor kapitallashuvining balans qiymatiga nisbati TBIO|traconpharma.com (TCON) - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati UBX (Unity Biotechnology, Inc.)